Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YANGJian , NARi-su , GuoChun-liang

Department of Hepatobiliary Surgery, Affiliated Hospital of Armed Police Logistics Institute Tianjin 300162, china;

Corresponding author：

YANGJian, Email: yangjianzg@126.com

Keywords：

HER 2 positive brest cancer; Capecitabine; Trastuzumab; Whole brain radiotherapy; Brain metastasis; Curative effect

DOI：

10.7507/1007-9424.20150118

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the curative effects of capecitabine and hessaitin combined with whole brain radiotherapy for treatment the HER2 positive breast cancer with brain metastasis. Methods The clinical data of 60 cases HER2-positive breast cancer patients with brain metastasis in our hospital in January 2004 to January 2012 were retrospectively analyzed.The 32 cases of observe group were treated by using capecitabine and herceptin combined with whole brain radiotherapy, and the 28 cases of control group were treated by using capecitabine and cisplatin combined with whole brain radiotherapy.The disease control rate, toxicity rate, and survival rate were evaluated. Results Compared with the control group, the disease control rate, toxicity rate, and survival rate were all better in observe group (P < 0.05). Conclusion The capecitabine and hessaitin combined with whole brain radiotherapy for treating patients with HER 2 positive brest cancer transferred to brain are effect and safe.

Citation： YANGJian, NARi-su, GuoChun-liang. Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(4): 447-450. doi: 10.7507/1007-9424.20150118 Copy

1.	王丹.多西他赛联合顺铂治疗乳腺癌的护理.药物与人, 2014, 27(2):80.
2.	Shan M, Wang X, Sun G, et al.A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China.Int J Clin Exp Med, 2014, 7(10):3482-3490.
3.	徐金明, 黎可, 陈轩, 等.曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察.重庆医学, 2013, 42(9):1025-1026.
4.	Li XJ, Zha QB, Xu XY, et al.Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC):a meta-analysis.Asian Pac J Cancer Prev, 2014, 15(22):9615-9619.
5.	Chiba A, Shimizu S, Yoshida A, et al.Eficacy and toxicity of lapatinib plus eapecitabine therapy in HER2-positive metastatic breast cancer.Gala To Kagaku Ryoho, 2012, 39(11):1675-1679.
6.	Niikura N, Saji S, Tokuda Y, et al.Brain metastases in breast cancer.Jpn J Clin Oncol, 2014, 44(12):1133-1140.
7.	高会全, 马学真, 董桂芝, 等.卡培他滨联合放疗治疗乳腺癌脑转移疗效分析.中华脑科疾病与康复杂志, 2013, 3(2):29-31.
8.	Lam SW, de Groot SM, Honkoop AH, et al.Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a multicentre, open-label, randomised phase 2 trial.Eur J Cancer, 2014, 50(18):3077-3088.
9.	李晶, 欧阳取长, 刘莉萍.吉西他滨联合曲妥珠单抗或顺铂治疗HER2阳性晚期乳腺癌的疗效观察.中国医师杂志, 2012, 14(11):1547-1549.
10.	Sasaki T.New guidelines to evaluate the response to treatment "RECIST".Gan To Kagaku Ryoho, 2000, 27(14):2179-2184.
11.	Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment.Cancer, 1981, 47(1):207-214.
12.	林琳, 洪熠, 陈侃, 等.乳腺癌脑转移全脑放疗后综合治疗的疗效观察.临床肿瘤学杂志, 2012, 17(11):1012-1015.
13.	Niwińska A, Murawska M, Pogoda K.Breast cancer brain metas-tases:differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT).Ann Oncol, 2010, 21(5):942-948.
14.	Miolo G, Muraro E, Martorelli D, et al.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.BMC Cancer, 2014, 14(1):954.
15.	DE Felice F, Musio D, Cassese R, et al.Radiotherapeutic treatment approaches for brain metastases.Anticancer Res, 2014, 34(12):6913-6918.
16.	Dimri K, Trehan R, Pandey AK, et al.Long term survival after whole brain radiotherapy for brain metastasis in follicular dendritic cell sarcoma.Indian J Cancer, 2014, 51(3):395-396.
17.	Hameed H, Cassidy J.Use of capecitabine in management of early colon cancer.Cancer Manag Res, 2011, 3:295-299.
18.	Tolaney S1, Burris H, Gartner E, et al.PhaseⅠ/Ⅱstudy of pilara-lisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat, 2015, 149(1):151-161.
19.	谢联斌, 谢莉, 袁丽方.多西紫杉醇联合卡培他滨治疗蒽环类耐药晚期三阴性乳腺癌的临床观察.中华乳腺病杂志, 2012, 4(3):339-340.
20.	Sotelo MJ, García-Sáenz JA, Manso L, et al.Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.J Cancer Res Ther, 2014, 10(4):967-972.
21.	Tolaney SM, Barry WT, Dang CT, et al.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med, 2015, 372(2):134-141.
22.	Aboutorabi A, Hadian M, Ghaderi H, et al.Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Glob J Health Sci, 2014, 7(1):37868.
23.	陈小松, 沈坤炜.曲妥珠单抗在HER2阳性乳腺癌治疗中的共识与争议.外科理论与实践, 2011, 16(6):601-602.
24.	Church DN, Modgil R, Guglani S, et al.Extended survival in women with brain metastases from HER-2 overexpressing breast cancer.Am J Clin Oncol, 2008, 31(3):250-254.
25.	Eichler AF, Kuter I, Ryan P, et al.Survival in patients with brain metastases from breast cancer:the importance of HER-2 status.Cancer, 2008, 112(11):2359-2367.

1. 王丹.多西他赛联合顺铂治疗乳腺癌的护理.药物与人, 2014, 27(2):80.
2. Shan M, Wang X, Sun G, et al.A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China.Int J Clin Exp Med, 2014, 7(10):3482-3490.
3. 徐金明, 黎可, 陈轩, 等.曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察.重庆医学, 2013, 42(9):1025-1026.
4. Li XJ, Zha QB, Xu XY, et al.Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC):a meta-analysis.Asian Pac J Cancer Prev, 2014, 15(22):9615-9619.
5. Chiba A, Shimizu S, Yoshida A, et al.Eficacy and toxicity of lapatinib plus eapecitabine therapy in HER2-positive metastatic breast cancer.Gala To Kagaku Ryoho, 2012, 39(11):1675-1679.
6. Niikura N, Saji S, Tokuda Y, et al.Brain metastases in breast cancer.Jpn J Clin Oncol, 2014, 44(12):1133-1140.
7. 高会全, 马学真, 董桂芝, 等.卡培他滨联合放疗治疗乳腺癌脑转移疗效分析.中华脑科疾病与康复杂志, 2013, 3(2):29-31.
8. Lam SW, de Groot SM, Honkoop AH, et al.Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a multicentre, open-label, randomised phase 2 trial.Eur J Cancer, 2014, 50(18):3077-3088.
9. 李晶, 欧阳取长, 刘莉萍.吉西他滨联合曲妥珠单抗或顺铂治疗HER2阳性晚期乳腺癌的疗效观察.中国医师杂志, 2012, 14(11):1547-1549.
10. Sasaki T.New guidelines to evaluate the response to treatment "RECIST".Gan To Kagaku Ryoho, 2000, 27(14):2179-2184.
11. Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment.Cancer, 1981, 47(1):207-214.
12. 林琳, 洪熠, 陈侃, 等.乳腺癌脑转移全脑放疗后综合治疗的疗效观察.临床肿瘤学杂志, 2012, 17(11):1012-1015.
13. Niwińska A, Murawska M, Pogoda K.Breast cancer brain metas-tases:differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT).Ann Oncol, 2010, 21(5):942-948.
14. Miolo G, Muraro E, Martorelli D, et al.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.BMC Cancer, 2014, 14(1):954.
15. DE Felice F, Musio D, Cassese R, et al.Radiotherapeutic treatment approaches for brain metastases.Anticancer Res, 2014, 34(12):6913-6918.
16. Dimri K, Trehan R, Pandey AK, et al.Long term survival after whole brain radiotherapy for brain metastasis in follicular dendritic cell sarcoma.Indian J Cancer, 2014, 51(3):395-396.
17. Hameed H, Cassidy J.Use of capecitabine in management of early colon cancer.Cancer Manag Res, 2011, 3:295-299.
18. Tolaney S1, Burris H, Gartner E, et al.PhaseⅠ/Ⅱstudy of pilara-lisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat, 2015, 149(1):151-161.
19. 谢联斌, 谢莉, 袁丽方.多西紫杉醇联合卡培他滨治疗蒽环类耐药晚期三阴性乳腺癌的临床观察.中华乳腺病杂志, 2012, 4(3):339-340.
20. Sotelo MJ, García-Sáenz JA, Manso L, et al.Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.J Cancer Res Ther, 2014, 10(4):967-972.
21. Tolaney SM, Barry WT, Dang CT, et al.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med, 2015, 372(2):134-141.
22. Aboutorabi A, Hadian M, Ghaderi H, et al.Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Glob J Health Sci, 2014, 7(1):37868.
23. 陈小松, 沈坤炜.曲妥珠单抗在HER2阳性乳腺癌治疗中的共识与争议.外科理论与实践, 2011, 16(6):601-602.
24. Church DN, Modgil R, Guglani S, et al.Extended survival in women with brain metastases from HER-2 overexpressing breast cancer.Am J Clin Oncol, 2008, 31(3):250-254.
25. Eichler AF, Kuter I, Ryan P, et al.Survival in patients with brain metastases from breast cancer:the importance of HER-2 status.Cancer, 2008, 112(11):2359-2367.

Previous Article
肝间叶性错构瘤1例报道
Next Article
Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content